Stefano Del Prato, EASD 2022: What to look out for at this year’s congress

touchENDOCRINOLOGY were delighted to catch up with EASD President Prof. Stefano Del Prato (University of Pisa, Italy) to discuss this year’s hybrid meeting, the highlights to look forward to and what the future of the EASD meeting is.

Questions

1. How do you feel about EASD 2022 being a hybrid event as opposed to the virtual congresses of recent years? (0:30)
2. What can we look forward to in the scientific programme of this year’s event? (1:16)
3. What will be the future of the EASD meeting? (3:04)

Disclosures: Stefano Del Prato has received grant/research support from AstraZeneca and Boehringer Ingelheim; has served on advisory boards for Applied Therapeutics, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Co, Merck & Co., Novartis Pharmaceuticals, Novo Nordisk and Sanofi; and has received honoraria from AstraZeneca, Boehringer Ingelheim, Eli Lilly and Co, Merck & Co., Novartis Pharmaceuticals, Novo Nordisk, Sanofi, and Takeda Pharmaceuticals.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.